36 results
Thumbnail

D1.274 - Anaphylaxis Risks in Beekeeping: The Importance of Developing a Health Education Program

Thumbnail

D1.284 - Trends in Recurrent Anaphylaxis Triggered by Food, Drug, and Insect Allergies from 2015 to 2021: A Population-Based Retrospective Cohort Study Using the National Insurance Claims Database of Japan

Thumbnail

D1.275 - Wheat-free diet restore the normal intestinal microbiome structure in patients with wheat-dependent exercise-induced anaphylaxis

Thumbnail

D1.276 - Social #anaphylaxis: how social media reveals shifting trends in public health concerns

Thumbnail

D1.278 - Chlorhexidine allergy in perioperative anaphylaxis: undeclared and overlooked

Thumbnail

D1.279 - Vit v 5: A Chitinase Implicated in Grape-Induced Anaphylaxis

Thumbnail

D1.282 - Identification of Thaumatin-like protein (Ole E 13) as a potential allergen in green olives, a case report

Thumbnail

D1.283 - Idiopathic anaphylaxis in a child, Alpha-gal syndrome. Is it an entity in children?

Thumbnail

D1.285 - Analysis of systemic food reactions in patients sensitized to Bet v1 in Madrid (Spain)

Thumbnail

D1.286 - Nebulized inhaled epinephrine versus epinephrine autoinjector for the treatment of food-induced anaphylaxis in young children – a randomized controlled clinical trial

Thumbnail

D1.287 - Lipid profiling of Co-factor Induced Anaphylaxis: The Impact of Exercise and Aspirin on metabolism

Thumbnail

D1.289 - Severe allergy to albumin after cesarean section

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years